Recent Advances in RP-HPLC Method Development and Validation for Empagliflozin: A Comprehensive Review
Main Article Content
Abstract
Empagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is widely prescribed for the treatment of type 2 diabetes mellitus, either alone or in fixed-dose combinations. Accurate and robust analytical methods are essential to ensure its quality, safety, and efficacy in bulk drug and pharmaceutical dosage forms. Among various techniques, reversed-phase high-performance liquid chromatography (RP-HPLC) remains the most widely adopted due to its versatility, sensitivity, and regulatory acceptance.This review provides a comprehensive overview of the development and validation of RP-HPLC methods for the estimation of Empagliflozin. Key physicochemical properties such as pKa, solubility, and UV absorbance characteristics are discussed in the context of chromatographic behavior. The article also outlines critical regulatory requirements from ICH Q2(R1/R2), pharmacopeial standards, and method validation parameters including specificity, linearity, precision, accuracy, robustness, and stability.A survey of published RP-HPLC methods is presented, covering both mono-component and combination formulations with Metformin, Linagliptin, and Sitagliptin. Comparative analysis of chromatographic conditions—such as mobile phase composition, detection wavelength, column type, and system suitability—highlights best practices and common challenges. The article further explores method sensitivity (LOD/LOQ), forced degradation studies, and the need for stability-indicating assays.
Future directions emphasize the adoption of green solvents, UHPLC technologies, Analytical Quality by Design (AQbD), and harmonization of analytical protocols. Recommendations are provided for bioanalytical extensions, improved impurity profiling, and establishment of standard or platform methods. This review serves as a valuable resource for researchers and analysts engaged in the pharmaceutical quality control and regulatory evaluation of Empagliflozin.
Article Details
Section
How to Cite
References
1. American Diabetes Association. (2023). Standards of Medical Care in Diabetes . Diabetes Care, 46(Suppl 1), S1–S2.
2. DeFronzo RA et al. (2015). The role of SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Care , 38(3), 352–363. DOI: https://doi.org/10.2337/dc14-3048
3. Zinman B et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine , 373(22), 2117–2128. DOI: https://doi.org/10.1056/NEJMoa1504720
4. Chatterjee S et al. (2020). Empagliflozin in combination therapies: A review. Diabetes & Metabolic Syndrome , 14(5), 1419–1426.
5. DrugBank. Empagliflozin.
6. Madure SP, Barge VI. (2020). RP-HPLC Method for Estimation of Empagliflozin. J Neonatal Surg , 9(4), 1–5.
7. Singh S et al. (2021). Analytical characterization of empagliflozin: pKa, solubility and stability. Int J Pharm Sci Rev Res , 70(2), 123–128.
8. Ahmad S, Maryam S. (2022). Stability indicating RP-HPLC method for Empagliflozin. Int J Pharm Drug Sci , 12(1), 45–52.
9. ICH Q2(R1). (2005). Validation of Analytical Procedures: Text and Methodology.
10. Snyder LR, Kirkland JJ, Dolan JW. (2010). Introduction to Modern Liquid Chromatography . Wiley.
11. Dong MW. (2006). Modern HPLC for Practicing Scientists . Wiley-Interscience.
12. Patil D et al. (2021). RP-HPLC Method Development and Validation for Estimation of Empagliflozin and Metformin. JIPBS , 8(3), 34–41.
13. Gaikwad NR, Khulbe RD. (2020). HPLC estimation of Empagliflozin in tablets. J Pharm Innov , 9(1), 1–5.
14. Vijaya T et al. (2021). RP-HPLC method for simultaneous estimation of Empagliflozin and Metformin. JPRI , 33(58B), 151–159.
15. ICH Q1A(R2). (2003). Stability Testing of New Drug Substances and Products .
16. ICH Q2(R1). (2005). Validation of Analytical Procedures: Text and Methodology.
17. ICH Q2(R2). (Draft, 2022). Revision of ICH Q2 Guideline on Validation of Analytical Procedures .
18. United States Pharmacopeia (USP) General Chapter <1225> "Validation of Compendial Procedures".
19. British Pharmacopoeia (2022). London: The Stationery Office.
20. FDA. (2022). Analytical Procedures and Methods Validation for Drugs and Biologics .
21. ICH Q1A(R2). (2003). Stability Testing of New Drug Substances and Products .
22. Gaikwad NR, Khulbe RD. (2020). HPLC estimation of Empagliflozin. J Pharm Innov , 9(1), 1–5. DOI: https://doi.org/10.7897/2277-4572.091160
23. Madure SP, Barge VI. (2020). RP-HPLC Method for Empagliflozin. J Neonatal Surg , 9(4), 1–5.
24. Singh S et al. (2021). Analytical characterization of empagliflozin: pKa and stability. Int J Pharm Sci Rev Res , 70(2), 123–128.
25. Snyder LR et al. (2010). Introduction to Modern Liquid Chromatography . Wiley.
26. Dong MW. (2006). Modern HPLC for Practicing Scientists . Wiley.
27. Patil D et al. (2021). RP-HPLC Method for Empagliflozin and Metformin. JIPBS , 8(3), 34–41.
28. Gaikwad NR, Khulbe RD. (2020). HPLC estimation of Empagliflozin in tablets. J Pharm Innov , 9(1), 1–5.
29. Madure SP, Barge VI. (2020). Stability-indicating RP-HPLC method for Empagliflozin. J Neonatal Surg , 9(4), 1–5.
30. Patil D et al. (2021). RP-HPLC method for estimation of Empagliflozin and Metformin. JIPBS , 8(3), 34–41.
31. Vijaya T et al. (2021). Simultaneous estimation of Empagliflozin and Linagliptin by RP-HPLC. JPRI , 33(58B), 151–159.
32. Chavhan A et al. (2020). RP-HPLC method for simultaneous estimation of Metformin, Sitagliptin, and Empagliflozin. Int J Pharm Sci , 12(4), 214–220.
33. Tobiszewski M. (2018). Green Analytical Chemistry—Theory and Practice. TrAC Trends in Analytical Chemistry , 98, 168–173.
34. Dong MW. (2006). Modern HPLC for Practicing Scientists . Wiley-Interscience. DOI: https://doi.org/10.1002/0471973106
35. Snyder LR, Kirkland JJ, Dolan JW. (2010). Introduction to Modern Liquid Chromatography . Wiley. DOI: https://doi.org/10.1002/9780470508183
36. Tobiszewski M. (2018). Green Analytical Chemistry—Theory and Practice. TrAC Trends in Analytical Chemistry , 98, 168–173.
37. Lionberger RA et al. (2008). Quality by Design: Concepts for ANDAs. AAPS Journal , 10(2), 268–276. DOI: https://doi.org/10.1208/s12248-008-9026-7
38. FDA. (2018). Bioanalytical Method Validation Guidance for Industry . U.S. Department of Health and Human Services.
39. Ahmad S, Maryam S. (2022). Stability-indicating HPLC method for Empagliflozin. Int J Pharm Drug Sci , 12(1), 45–52.
40. International Council for Harmonisation. ICH Q14: Analytical Procedure Development 2022.